Efficacy, Pharmacokinetics, and Safety of BI 695500 in Patients With Rheumatoid Arthritis
Efficacy, Pharmacokinetics, and Safety of BI 695500 Versus Rituximab in Patients With Moderately to Severely Active Rheumatoid Arthritis: a Randomized, Double-blind, Parallel Arm, Multiple Dose, Active Comparator Trial.
Sponsor: Boehringer Ingelheim
Terminated
substance discontinued
Other terminated trials from Boehringer Ingelheim
Other Arthritis, Rheumatoid trials with similar outcome
A PHASE3 clinical study on Arthritis, Rheumatoid, this trial is terminated or withdrawn. The trial is conducted by Boehringer Ingelheim and has accumulated 10 data snapshots since 2012. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
10 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE3
-
Dec 2021 — Jul 2024 [monthly]
Terminated PHASE3
-
Jan 2021 — Dec 2021 [monthly]
Terminated PHASE3
▶ Show 5 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE3
-
Feb 2018 — Jun 2018 [monthly]
Terminated PHASE3
-
Nov 2017 — Feb 2018 [monthly]
Terminated PHASE3
Status: Completed → Terminated
-
Mar 2017 — Nov 2017 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Jan 2017 — Mar 2017 [monthly]
Active Not Recruiting PHASE3
First recorded
Sep 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Boehringer Ingelheim
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
A Coruña, Spain , Albuquerque, United States , Almada, Portugal , Amadora, Portugal , Athens, Greece , Aveiro, Portugal , Barcelona, Spain , Beckley, United States , Berlin, Germany , Bialystok, Poland and 87 more locations